drugset / Trial / NCT03970798

A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin

NCT03970798

Phase 1 Completed 50 enrolled Kyowa Kirin, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the influence of repeated oral doses of KW-6356 on the pharmacokinetics of index substrates for CYP3A4/5, CYP1A2 and BCRP.

Timeline

Start
2019-05-22
Primary completion
2019-07-31
Completion
2019-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Caffeine Small molecule
Subject Midazolam Small molecule
Subject Rosuvastatin Small molecule
Subject SIPAGLADENANT Small molecule

Indications